The purpose of KUTTAM is to promote the development of high value-added biomedical devices based on basic scientific research and domestic possibilities, and to encourage and support the work to be carried out in the relevant area. KUTTAM aims to be a national leader in the field by influencing the world with translational research in the health sector. In this context, KUTTAM infrastructure provides with unparalleled opportunities for integrated research in pharmacology, biochemistry, molecular biology and genetics and material sciences.

Established with a 25 million lira investment over a 5-year period by İşbank, the Center for Infectious Diseases aims to conduct research against the risk of local and global-scale infectious diseases that may threaten the health of Turkish people, providing a service of strategic importance by reducing the external dependence of our country. Conducting advanced research on infectious diseases, the Center helps develop new methods of diagnosis and treatment, and by qualitatively and quantitatively developing its human resources, aims to ensure that the obtained knowledge is disseminated to the public.

The first ERA Chair Grant awarded in Türkiye to Koç University Transplant Immunology Research Center of Excellence (TIREX), with a budget of 2.5 million Euros.

 

Transplant Immunology Research Centre of Excellence (TIREX) is designed to capitalize on these strengths and to create a hub for translational research to improve the lives of transplant recipients. The goal of the ERA Chair project is to set up a multi-disciplinary research group on Transplant Immunology focusing on novel laboratory and clinical approaches to benefit patients with organ failure. The Transplant Immunology Research Centre of Excellence and its Transplant Immunology Lab will be working on the following research topics:

 

• Pre-treatment and improvement of preservation of the donor organ: Development of novel techniques and treatments to restore organ function and to improve its resistance to cell death and immune attack before transplantation

• Post-transplant care: Personalised immunosuppression to the individual patients to improve the results of transplantation

• Prevention and treatment of sensitisation in patients with a failing transplant: Improvement of these patients’ chances for another successful transplant

Established as part of the Koç University Hospital, the Clinical Trials Unit (CTU) and the Phase 1 Clinical Trial Center (CTC) bring talented young people and prominent academics together and contribute to interdisciplinary research. The CTC became Türkiye’s first high-risk drug development center to be certified by the Turkish Medicines and Medical Devices Agency. The Unit provides scientific and technical support required at every step of clinical research, from design to effective and timely completion. The CTC was designed for the management of multicenter randomized controlled trials in both pharmaceutics and biomedical equipment approved by ethical committees. In addition to physical infrastructure, both the CTU and the CTC provide researchers with all required expertise, consultancy and support.